Autism CBD Trial On Children Advances As Israeli Company Enrolls First Five Patients
SciSparc Ltd. (NASDAQ:SPRC) announced on Tuesday that the first five patients have been enrolled and dosed into its ongoing clinical trial in children suffering from autism spectrum disorder (ASD) at the Soroka Medical Center in Israel.
What Happened
The Israeli specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system enrolled the first patient in March to its clinical trial assessing the efficacy and safety of its cannabidiol (CBD)– based drug for the treatment of children with autism spectrum disorder.
The double-blind, randomized and placebo-controlled trial uses SciSparc’s proprietary SCI-210, a combination of CBD and CannAmide– the company’s Palmitoylethanolamide – which …